R&D
A certificate of analysis should be evidence, not a sales do...
Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.
R&D
From phase 1 to phase 3: Scaling radiopharmaceutical trials
Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
Patients
Patients not just at the table, but creating their own: In c...
Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.
R&D
Gravity is an experimental variable pharma has rarely been a...
Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.
Digital
Sponsored
Antiviral development in the age of AI: From pre-IND to earl...
hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
